Metallo-β-lactamases producing Pseudomonas aueroginosa represents a challenging concern especially in chronic colonization of bronchiectasis cases owing to progressive tissue damage, inflammation, frequent exacerbation and lack of response to antimicrobial agents. Objectives: This cross-sectional study was conducted to highlighten the antimicrobial and molecular pattern of Pseudomonas aueroginosa isolates from bronchiectasis cases and assess their clinical outcome. Methodology: ninety-eight sputum and endotracheal aspirates were collected from bronchiectasis inpatients of Chest Department, Zagazig University Hospitals. Conventional identification and API20 NE were performed. Combined disc test and E-test were done, confirmed by PCR, to detect metallo-β-lactamases. Results: A total of 43 (43.9%) Pseudomonas were isolated, 16 (37.2%) were metallo β-lactamases and multidrug resistant. E. test had the best sensitivity and specificity. Both IMP-1 and VIM-1 genes were detected. The majority of isolates were IPM-1 positive. Conclusion: P. aeruginosa, is blamable for infection in more than 40% of bronchiectactic patients being a high-risk group. Combined disk test is a reliable, cheap and simple screening tool especially in low-resources laboratories. This study raised the concern of co-existing mechanism for both quinolone and carbapenem resistance for more investigation. Current results linked lab detection of MβL P. aeruginosa with inferior spirometry and lengthy hospital stay.